GU Cancers 2022 | ARASENS: the addition of darolutamide to ADT and docetaxel for the treatment of mHSPC

Simon J. Crabb, PhD, MBBS, Southampton Experimental Cancer Medicine Centre, Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK, talks on data from the Phase III ARASENS (NCT02799602) trial which showed similarities to those of the Phase III PEACE-1 (NCT01957436). The ARASENS trial demonstrated a possible benefit to the addition of the oral androgen receptor (AR) antagonist, dialuramide, in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving androgen-deprivation therapy (ADT) and docetaxel. The ARASENS trial showed a positive survival advantage as well as positive secondary endpoints. However, this patient population currently receives novel hormonal agents including abiraterone, enzalutamide and apalutamide in the UK. Dr Crabb questions whether the data from the ARASENS study justifies intensive triple therapy and emphasizes the need to decipher which subsets of patients would be appropriate for such intensive treatment. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.